ESMO26: Key data breathing new life into the lung cancer field

Clinical Trials Arena brings you the lung cancer highlights from ESMO 2026, with readouts from MSD, AstraZeneca, Roche and BioNTech. Clinical Trials Arena brings you the lung cancer highlights from ESMO 2026, with readouts from key players MSD, AstraZeneca, Roche and BioNTech. Clinical Trials Arena brings you the lung cancer highlights from the 2026 ESMO congress in Madrid. Credit: Net Vector / Shutterstock.com. The 2026 European Society for Medical Oncology (ESMO) congress is drawing to a close but has been packed with potentially paradigm-shifting readouts across several solid tumour indications, with lung cancer remaining a key focus. While there are…

Source: Clinical Trials Arena